Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: A phase I/II study

Bone Marrow Transplantation

Volumn 19, Issue 5, 1997, Pages 435-442

  Robinson, N ^a   Benyunes, M C ^a   Thompson, J A ^a   York, A ^a   Petersdorf, S ^a   Press, O ^a   Lindgren, C ^a   Chauncey, T ^a   Buckner, C D ^a   Bensinger, W I ^a   Appelbaum, F R ^a   Fefer, A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autologous BMT; Immunotherapy; Interleukin 2; PBSC

Indexed keywords

CARMUSTINE; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANOREXIA; ARTICLE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG TOLERABILITY; FEMALE; FEVER; GRAM NEGATIVE INFECTION; HALLUCINATION; HICCUP; HODGKIN DISEASE; HUMAN; HUMAN CELL; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; RECURRENCE RISK; SIDE EFFECT; STEM CELL TRANSPLANTATION; STOMATITIS; VASCULAR DISEASE; WEIGHT GAIN;

EID: 0031047464     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700687     Document Type: Article

References (36)

1. Attal M, Blaise D, Marit G et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995; 86: 1619-1628.
2. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
3. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
4. Petersen FB, Lynch MH, Clift RA et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 1993; 11: 1353-1360.
5. Meloni G, Foa R, Vignetti M et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158-2163.
6. Maraninchi D, Blaise D, Viens P et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991; 78: 2182-2187.
7. Gisselbrecht C, Maraninchi D, Pico JL et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994; 83: 2081-2085.
8. Benyunes M, Fefer A. Interleukin-2 in the treatment of hematologic malignancies. In: Atkins M, Mier J (eds). Therapeutic Applications of Interleukin-2. Marcel Dekker: New York, 1993, pp 163-175.
9. Peest D, Leo R, Bloche S et al. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. Br J Haematol 1995; 89: 328-337.
10. Higuchi CM, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561-2568.
11. Benyunes MC, Massumoto C, York A et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159-163.
12. Benyunes MC, Higuchi C, York A et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995; 16: 283-288.
13. Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447-1456.
14. Bast RC, Ritz J, Lipton JM et al. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 1983; 43: 1389-1394.
15. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
16. Higuchi CM, Thompson JA, Cox T et al. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 1989; 49: 5509-5513.
17. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Horning SJ, Negrin RS, Chao JC et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2552-2558.
19. Oshimi K, Oshimi Y, Akutsu M et al. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938-948.
20. Neubauer MA, Benyunes MC, Thompson JA et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1994; 13: 311-316.
21. Massumoto C, Benyunes MC, Sale G et al. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant 1996; 17: 351-356.
22. Thompson JA, Lee DJ, Lindgren CG et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res 1989; 49: 235-240.
23. Thompson JA, Lee DJ, Lindgren CG et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immuno-modulation. J Clin Oncol 1988; 6: 669-678.
24. Blaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092-1097.
25. Boldt DH, Ellis TM. Biological effects of Interleukin-2 administration on the immune system. In: Atkins M, Mier J (eds). Therapeutic Applications of Interleukin-2. Marcel Dekker: New York, 1993, pp 73-91.
26. Reusser P, Fisher LD, Buckner CD et al. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990; 75: 1888-1894.
27. Verdonck LF, de-Gast GC, van-Heugten HG et al. Cytomegalovirus infection causes delayed platelet recovery after bone marrow transplantation. Blood 1991; 78: 844-848.
28. Klempner MS, Snydman DR. Infectious complications associated with Interleukin-2. In: Atkins M, Mier J (eds). Therapeutic Applications of Interleukin-2. Marcel Dekker: New York, 1993, pp 409-424.
29. Blaise D, Stoppa AM, Viens P et al. Intensive immunotherapy with recombinant IL2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections. Bone Marrow Transplant 1992; 10: 193-194.
30. Reittie JE, Gottlieb D, Heslop HE et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351-1358.
31. Caligiuri MA, Murray C, Robertson MJ et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993; 91: 123-132.
32. Robinson N, Benyunes MC, York A et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Blood 1996; 86 (Suppl. 1): 962a (Abstr. 3837).
33. Fefer A, Benyunes MC, Massumoto C et al. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1993; 20 (Suppl. 9): 41-45.
34. Mehta J, Powles R, Singhal S et al. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant 1995; 15: 652-653.
35. Demirer T, Petersen FB, Bensinger WI et al. Autologous transplantation with peripheral blood stem cells collected after granulocyte-colony stimulating factor in patients with acute myelogenous leukemia. Bone Marrow Transplant 1996; 18: 29-34.
36. Fefer A, Benyunes MC. Interleukin-2 as consolidative immunotherapy after clinical autologous bone marrow transplantation. In: Spitzer T, Mazumder A (eds). Immunotherapy and Bone Marrow Transplantation. Futura Publishing: Armonk, NY, 1995, pp 101-120.